Ikena Oncology, Inc.
For the period ended Jun 30, 2025. Filed Jul 24, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 24, 2025
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(11,386) | $(29,876) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 174 | 311 |
| Net accretion of discounts on marketable securities | (243) | (817) |
| Stock-based compensation expense | 1,362 | 3,280 |
| Non-cash operating lease expense | 1,074 | 907 |
| Loss on disposal of property and equipment | — | 99 |
| Impairment of assets held for sale | — | 742 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (588) | (539) |
| Deposits and other assets | 940 | 2,796 |
| Accounts payable | (385) | (658) |
| Accrued expenses and other current liabilities | (3,119) | (5,488) |
| Operating lease liabilities | (1,844) | (1,646) |
| Other long-term liabilities | 31 | 83 |
| Net cash used in operating activities | (13,984) | (30,806) |
| Cash flows from investing activities: | ||
| Proceeds from sale of property and equipment | — | 245 |
| Purchases of marketable securities | (23,184) | (72,265) |
| Proceeds from sales and maturities of marketable securities | 71,065 | 27,200 |
| Amounts loaned under note receivable | (15,000) | — |
| Net cash provided by (used in) investing activities | 32,881 | (44,820) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 18,897 | (75,626) |
| Cash, cash equivalents and restricted cash, beginning of period | 40,265 | 121,172 |
| Cash, cash equivalents and restricted cash, end of period | $59,162 | $45,546 |
| Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets: | ||
| Cash and cash equivalents | $58,290 | $44,268 |
| Restricted cash included in deposits and other assets | 872 | 1,278 |
| Cash, cash equivalents and restricted cash, end of period | $59,162 | $45,546 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.